United States securities and exchange commission logo April 14, 2022 Eric A. Adams Chief Executive Officer InMed Pharmaceuticals Inc. Suite 310 815 West Hastings Street Vancouver, British Columbia V6C 1B4 Canada Re: InMed Pharmaceuticals Inc. Registration Statement on Form S-3 Filed April 7, 2022 File No. 333-264187 Dear Mr. Adams: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Michael Davis at 202-551-4385 or Christine Westbrook at 202-551- 5019 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brian P. Fenske, Esq.